MedTrace Logo

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

NCT03886311 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-02-24

No results posted yet for this study

Summary

This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.

Conditions

  • Sarcoma

Interventions

DRUG

Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]

Talimogene laherparepvec, 1Bil is given intratumorally every 2 weeks according to tumor size

DRUG

Nivolumab IV Soln 100 MG/10ML

NIVOLUMAB 240 mg IV over 30 min q 2 weeks

DRUG

Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution

TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks

Sponsors & Collaborators

  • Sarcoma Oncology Research Center, LLC

    lead OTHER

Principal Investigators

  • Sant P Chawla, MD · Sarcoma Oncology Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2030-12-31
Completion
2031-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03886311 on ClinicalTrials.gov